141 related articles for article (PubMed ID: 38146039)
1. Missing the mark? Exploratory analysis of the 10-year-old cutoff as an independent marker of high-risk disease in pediatric B-ALL.
George PE; DeGroote NP; Henderson M; Jordan K; Ziworitin-Ogola C; Castellino SM; Miller TP
Pediatr Blood Cancer; 2024 Mar; 71(3):e30825. PubMed ID: 38146039
[TBL] [Abstract][Full Text] [Related]
2. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group.
Burkhardt B; Reiter A; Landmann E; Lang P; Lassay L; Dickerhoff R; Lakomek M; Henze G; von Stackelberg A
J Clin Oncol; 2009 Jul; 27(20):3363-9. PubMed ID: 19433688
[TBL] [Abstract][Full Text] [Related]
3. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).
Schultz KR; Pullen DJ; Sather HN; Shuster JJ; Devidas M; Borowitz MJ; Carroll AJ; Heerema NA; Rubnitz JE; Loh ML; Raetz EA; Winick NJ; Hunger SP; Carroll WL; Gaynon PS; Camitta BM
Blood; 2007 Feb; 109(3):926-35. PubMed ID: 17003380
[TBL] [Abstract][Full Text] [Related]
4. Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials.
Eckert C; Parker C; Moorman AV; Irving JA; Kirschner-Schwabe R; Groeneveld-Krentz S; Révész T; Hoogerbrugge P; Hancock J; Sutton R; Henze G; Chen-Santel C; Attarbaschi A; Bourquin JP; Sramkova L; Zimmermann M; Krishnan S; von Stackelberg A; Saha V
Eur J Cancer; 2021 Jul; 151():175-189. PubMed ID: 34010787
[TBL] [Abstract][Full Text] [Related]
5. Aberrant IKZF1 gene as relapse predictor in standard-risk pediatric patients with B-cell precursor acute lymphoblastic leukaemia.
Vshyukova VS; Krasko OV; Yanchanka DA; Meleshko AN
Int J Lab Hematol; 2022 Aug; 44(4):769-776. PubMed ID: 35505470
[TBL] [Abstract][Full Text] [Related]
6. [Therapeutic strategies for childhood high-risk acute lymphoblastic leukemia].
Lu XT
Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 45(2):327-32. PubMed ID: 23591360
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.
Ribera JM; Ortega JJ; Oriol A; Granada I; Hernández-Rivas JM; Parody R; Bethencourt C; Rivas C; Bastida P; del Potro E; González-Valentín ME; Moreno MJ; Besalduch J; Fernández-Calvo J; Tormo M; Arias J; Molinés A; Sanz MA; Maldonado J; Millá F; Feliu E; San Miguel JF;
Haematologica; 2002 Feb; 87(2):154-66. PubMed ID: 11836166
[TBL] [Abstract][Full Text] [Related]
8. [Clinical and Prognostic analysis of 43 Children with Mature B-cell Non-Hodgkin's Lymphoma/Acute Lymphoblastic Leukemia].
Guo J; Zhu YP; Gao J; Li Q; Jia CS; Zhou CY; Guo X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):72-9. PubMed ID: 26913397
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of end of induction measurable residual disease monitoring in B-cell acute lymphoblastic leukemia: A single center experience.
Arunachalam AK; Selvarajan S; Mani T; Janet NB; Maddali M; Lionel SA; Kulkarni U; Korula A; Aboobacker FN; Abraham A; George B; Balasubramanian P; Mathews V
Cytometry B Clin Cytom; 2023 Nov; 104(6):440-452. PubMed ID: 37555390
[TBL] [Abstract][Full Text] [Related]
10. Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study.
Lepretre S; Touzart A; Vermeulin T; Picquenot JM; Tanguy-Schmidt A; Salles G; Lamy T; Béné MC; Raffoux E; Huguet F; Chevallier P; Bologna S; Bouabdallah R; Benichou J; Brière J; Moreau A; Tallon-Simon V; Seris S; Graux C; Asnafi V; Ifrah N; Macintyre E; Dombret H
J Clin Oncol; 2016 Feb; 34(6):572-80. PubMed ID: 26644537
[TBL] [Abstract][Full Text] [Related]
11. High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.
Cario G; Rhein P; Mitlöhner R; Zimmermann M; Bandapalli OR; Romey R; Moericke A; Ludwig WD; Ratei R; Muckenthaler MU; Kulozik AE; Schrappe M; Stanulla M; Karawajew L
Haematologica; 2014 Jan; 99(1):103-10. PubMed ID: 23911702
[TBL] [Abstract][Full Text] [Related]
12. Philadelphia chromosome-positive acute lymphoblastic leukemia.
Lestingi TM; Hooberman AL
Hematol Oncol Clin North Am; 1993 Feb; 7(1):161-75. PubMed ID: 8449857
[TBL] [Abstract][Full Text] [Related]
13. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials.
Boissel N; Auclerc MF; Lhéritier V; Perel Y; Thomas X; Leblanc T; Rousselot P; Cayuela JM; Gabert J; Fegueux N; Piguet C; Huguet-Rigal F; Berthou C; Boiron JM; Pautas C; Michel G; Fière D; Leverger G; Dombret H; Baruchel A
J Clin Oncol; 2003 Mar; 21(5):774-80. PubMed ID: 12610173
[TBL] [Abstract][Full Text] [Related]
14. Aneuploidy in childhood B cell acute lymphoblastic leukaemia - also a relevant prognostic factor in relapsed disease?
Zugmaier G
Br J Haematol; 2019 Mar; 184(6):895-896. PubMed ID: 30723892
[No Abstract] [Full Text] [Related]
15. Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.
Tzortzatou-Stathopoulou F; Papadopoulou AL; Moschovi M; Botsonis A; Tsangaris GT
J Pediatr Hematol Oncol; 2001 Dec; 23(9):591-7. PubMed ID: 11902303
[TBL] [Abstract][Full Text] [Related]
16. Prognosis of haploidentical hematopoietic stem cell transplantation in non-infant children with t(v;11q23)/MLL-rearranged B-cell acute lymphoblastic leukemia.
Bai L; Cheng YF; Lu AD; Suo P; Wang Y; Zuo YX; Yan CH; Wu J; Jia YP; Sun YQ; Chen YH; Chen H; Liu KY; Han W; Xu LP; Wang JB; Tang XF; Chen HR; Zhang LP; Huang XJ
Leuk Res; 2020 Apr; 91():106333. PubMed ID: 32109757
[TBL] [Abstract][Full Text] [Related]
17. Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia.
Lauten M; Möricke A; Beier R; Zimmermann M; Stanulla M; Meissner B; Odenwald E; Attarbaschi A; Niemeyer C; Niggli F; Riehm H; Schrappe M
Haematologica; 2012 Jul; 97(7):1048-56. PubMed ID: 22271901
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of myeloid-associated antigen expression on blast cells in children with acute lymphoblastic leukemia. The Austrian Pediatric Oncology Group.
Fink FM; Köller U; Mayer H; Haas OA; Grümayer-Panzer ER; Urban C; Dengg K; Mutz I; Tüchler H; Gatterer-Menz I
Med Pediatr Oncol; 1993; 21(5):340-6. PubMed ID: 8492748
[TBL] [Abstract][Full Text] [Related]
19. Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group.
Salzer WL; Devidas M; Carroll WL; Winick N; Pullen J; Hunger SP; Camitta BA
Leukemia; 2010 Feb; 24(2):355-70. PubMed ID: 20016527
[TBL] [Abstract][Full Text] [Related]
20. Risk classification at the time of diagnosis differentially affects the level of residual disease in children with B-precursor acute lymphoblastic leukemia after completion of therapy.
Okcu MF; Roberts WM; Johnston DA; Ouspenskaia MV; Papusha VZ; Brandt MA; Zipf TF
Leuk Res; 2003 Aug; 27(8):743-50. PubMed ID: 12801533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]